Market Cap 123.81M
Revenue (ttm) 47.98M
Net Income (ttm) -68.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -142.91%
Debt to Equity Ratio 0.00
Volume 451,800
Avg Vol 672,660
Day's Range N/A - N/A
Shares Out 56.28M
Stochastic %K 13%
Beta 1.47
Analysts Sell
Price Target $5.00

Company Profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candi...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 242 1600
Address:
675 Massachusetts Avenue, 14th Floor, Cambridge, United States
mdboss
mdboss Oct. 25 at 12:01 PM
$SPRO The BIG news of this past week was the 2AM GSK/SPRO Tebi press release that triggered the exchange of 10 million shares before the open and another 2.75 million shares between a shockingly narrow price range of 2.30 to 2.50. Premarket action took SPRO up to 2.95 on very high volume. GSK owns approx 15% of SPRO with a very low cost basis. GSK reports a 3.5 billion a year market opportunity for Tebi listing it as their #1 prospect for 2026. Tebi will be a cash cow for GSK for years to come. A 1-2 billion outlay to buy out Spero is highly likely in my opinion. I have conviction and skin in this game with now just shy of 1% ownership. I believe the NDA is imminent which GSK confirmed this week. The FDA has already approved another oral carbapenem for uUTI. The crown jewel is Tebi for cUTI and it will be approved with a BO at a share price of $20 to $35. Godspeed longs.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 5:11 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SPRO Current Share Price: $2.26 Contracts: $SPRO April 17, 2026 $2 Calls Scale in: $0.40- $0.49 Scale out: $0.63-$0.81 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Wayne2022
Wayne2022 Oct. 24 at 8:09 PM
$SPRO anyone thinks $SPRO will qualify for CNPV program?
1 · Reply
MonYversE
MonYversE Oct. 23 at 9:45 PM
$SPRO 🤑
0 · Reply
JoeWo
JoeWo Oct. 23 at 7:11 PM
$SPRO Worse than watching paint dry... Like watching water evaporate during a 100% humid day.
0 · Reply
DARKP00L
DARKP00L Oct. 23 at 4:46 PM
$SPRO this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
jreddyN
jreddyN Oct. 23 at 6:15 AM
$SPRO GSK License Agreement, Spero is entitled to receive a $25.0 million milestone for GSK submitting an NDA for their licensed product. Also under that agreement: up to $101.0 million in commercial “first‐sales” milestone payments (after the NDA/approval) and up to $225.0 million in sales-based milestone payments.
0 · Reply
DDel
DDel Oct. 22 at 11:55 PM
$SPRO buying the dips, until gsk buys it all. i don't flip for pennies, no thanks, i only go for dollars. long investor and very
0 · Reply
Stockrocker77
Stockrocker77 Oct. 22 at 11:29 PM
$SPRO GSK already holds a license agreement with $SPRO, they can benefit from product sales simply by paying the agreed royalties, without the need to purchase the entire company. A buyout would only make strategic sense if GSK sought full control, higher profit margins, or other long term advantages that the current license arrangement does not provide. So if you are a long term investor, you will profit on both scenarios.
2 · Reply
ProfessorGamma
ProfessorGamma Oct. 22 at 11:08 PM
$SPCE $HOLO $INTU $SPRO How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI
0 · Reply
Latest News on SPRO
Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:32 PM EDT - 2 months ago

Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript


Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:31 PM EDT - 7 months ago

Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript


mdboss
mdboss Oct. 25 at 12:01 PM
$SPRO The BIG news of this past week was the 2AM GSK/SPRO Tebi press release that triggered the exchange of 10 million shares before the open and another 2.75 million shares between a shockingly narrow price range of 2.30 to 2.50. Premarket action took SPRO up to 2.95 on very high volume. GSK owns approx 15% of SPRO with a very low cost basis. GSK reports a 3.5 billion a year market opportunity for Tebi listing it as their #1 prospect for 2026. Tebi will be a cash cow for GSK for years to come. A 1-2 billion outlay to buy out Spero is highly likely in my opinion. I have conviction and skin in this game with now just shy of 1% ownership. I believe the NDA is imminent which GSK confirmed this week. The FDA has already approved another oral carbapenem for uUTI. The crown jewel is Tebi for cUTI and it will be approved with a BO at a share price of $20 to $35. Godspeed longs.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 5:11 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SPRO Current Share Price: $2.26 Contracts: $SPRO April 17, 2026 $2 Calls Scale in: $0.40- $0.49 Scale out: $0.63-$0.81 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Wayne2022
Wayne2022 Oct. 24 at 8:09 PM
$SPRO anyone thinks $SPRO will qualify for CNPV program?
1 · Reply
MonYversE
MonYversE Oct. 23 at 9:45 PM
$SPRO 🤑
0 · Reply
JoeWo
JoeWo Oct. 23 at 7:11 PM
$SPRO Worse than watching paint dry... Like watching water evaporate during a 100% humid day.
0 · Reply
DARKP00L
DARKP00L Oct. 23 at 4:46 PM
$SPRO this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
jreddyN
jreddyN Oct. 23 at 6:15 AM
$SPRO GSK License Agreement, Spero is entitled to receive a $25.0 million milestone for GSK submitting an NDA for their licensed product. Also under that agreement: up to $101.0 million in commercial “first‐sales” milestone payments (after the NDA/approval) and up to $225.0 million in sales-based milestone payments.
0 · Reply
DDel
DDel Oct. 22 at 11:55 PM
$SPRO buying the dips, until gsk buys it all. i don't flip for pennies, no thanks, i only go for dollars. long investor and very
0 · Reply
Stockrocker77
Stockrocker77 Oct. 22 at 11:29 PM
$SPRO GSK already holds a license agreement with $SPRO, they can benefit from product sales simply by paying the agreed royalties, without the need to purchase the entire company. A buyout would only make strategic sense if GSK sought full control, higher profit margins, or other long term advantages that the current license arrangement does not provide. So if you are a long term investor, you will profit on both scenarios.
2 · Reply
ProfessorGamma
ProfessorGamma Oct. 22 at 11:08 PM
$SPCE $HOLO $INTU $SPRO How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI
0 · Reply
Bigos
Bigos Oct. 22 at 4:49 PM
$SPRO Mostly just @mdboss pumping a "buyout" without any substance or statements from the company to back it up. He did this in a different stock before. He thinks if he says something enough times, it will come true. So far, his predictions have fallen flat. He previously guaranteed a buyout would have in July.
0 · Reply
buyandsold
buyandsold Oct. 22 at 12:50 PM
$SPRO why is everyone so convinced of a buyout, GSK can just pay royalties as initially agreed. They went to a lot of trouble to agree how to split profit from an approved drug so why would they not just stick to terms they thought through very carefully. They dont need to pay now based on projections of sales.
1 · Reply
Inc82
Inc82 Oct. 22 at 2:57 AM
$SPRO Like I said before, one step forward and three steps backward.
0 · Reply
JoeWo
JoeWo Oct. 22 at 1:00 AM
$SPRO What a dud turd. Going to keep waiting for earnings, NDA, then buyout. Probably not till January to complete all 3. GLTA.
0 · Reply
Zenlama
Zenlama Oct. 21 at 8:26 PM
$SPRO Who would rather travel to Hospital, or clinic, pay for an administered injection, the Drug, and hospital visit, or stay home take a pill and save all that time, money, and hassle?
0 · Reply
jreddyN
jreddyN Oct. 21 at 6:29 PM
$SPRO GSK plans to submit regulatory filings in Q4 2025 based on these results. The drug has already received Qualified Infectious Disease Product and Fast Track designations from the FDA, potentially expediting its review process.
0 · Reply
Willdowdell
Willdowdell Oct. 21 at 5:01 PM
$SPRO it’s all about oral versus IV
0 · Reply
mdboss
mdboss Oct. 21 at 4:35 PM
$SPRO Volume precedes movement! #gotvolume
0 · Reply
TrkDvr
TrkDvr Oct. 21 at 3:44 PM
$SPRO I was confused by the term "demonstrated non-inferiority of one drug versus another" & " stopped early for demonstrating non-inferiority" Turns out this action demonstrates the robust results from the trials - requiring no further trials before submission. This makes SPRO ora; drug a strong candidate for approval.
2 · Reply
mdboss
mdboss Oct. 21 at 3:17 PM
$SPRO The overnight PR spoke volumes. It was the first Tebi PR released on London and not EST SPRO time. It also confirmed that GSK is full steam ahead on NDA submission and a perfunctory FDA approval. It was tantamount to submission of the NDA. I found it fascinating to see the congratulatory/celebratory vibe of the PR. Approximately 10 million shares before the bell exchanged hands above yesterday's close. Somebody liked the 2AM news. I see it as a friggin GREEN LIGHT! Let's have fun longs. Show me the money GSK!!!!!!!!!!
0 · Reply
Olg59
Olg59 Oct. 21 at 3:12 PM
$SPRO Still a BUY!
0 · Reply
Invest2live
Invest2live Oct. 21 at 2:55 PM
$SPRO 73% already; checkout $IBIO and $CUE
0 · Reply